Description
Developer of a biopharma therapy designed to cure bladder cancer. The company's therapy work by combining the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists, enabling doctors to cure bladder cancer with reduced adverse events associated with traditional BCG.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Grant | 01-Jun-2022 | $256K | 00000 | Completed | Generating Revenue | |
4. Grant | 08-Jul-2019 | 00000 | 00000 | Completed | Generating Revenue | |
3. Early Stage VC | 02-Jul-2019 | 00000 | 00000 | Completed | Generating Revenue | |
2. Accelerator/Incubator | 28-Jun-2019 | Completed | Generating Revenue | |||
1. Grant | 23-Feb-2018 | Completed | Generating Revenue |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Todd Wallach | Chief Business Officer | ||
Trinity Bivalacqua Ph.D | Co-Founder | ||
William Bishai Ph.D | Co-Founder |
Name | Representing | Role | Since |
---|---|---|---|
Ambaw Bellete | OncoSTING | Chairman | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
National Institutes of Health | Government | 000 0000 | 000000 0 | ||
National Science Foundation | Government | 000 0000 | 000000 0 | ||
Johns Hopkins University Endowment | Limited Partner | 000 0000 | 000000 0 | ||
TEDCO | Venture Capital | Minority | 000 0000 | 000000 0 |